



**NORRIS**  
**MEDICINES LIMITED**



**Factory** : Plot No. 801/P, 901/3-5, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Regd. Office** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Telephone** : (02646) 223462, 227530  
**Fax** : (02646) 250126  
**E-mail** : contact@norrispharma.com  
**Website** : www.norrispharma.com  
**CIN** : 124230MH1990PLC058071

New CIN L24230GJT1990PLC086581

To,  
The Manager,  
Department of Corporate Relationship,  
BSE Limited  
25<sup>th</sup> P. J. Towers,  
Dalal Street, Fort,  
Mumbai – 400 001

**Scrip Code: 524414**

**Subject: Submission of Standalone Unaudited Financial Results in compliance  
With Regulation 33 of SEBI (LODR) Regulations, 2015**

Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the following:

- 1) Standalone Unaudited Financial Results of the Company for the Quarter and Nine months ended on 31<sup>st</sup> December, 2021.
- 2) Limited Review Report on Standalone Unaudited Financial Results for the quarter and Nine months ended on 31<sup>st</sup> December, 2021.

Kindly take the aforesaid information on your record and oblige.

Thanking you,

Yours truly,  
For Norris Medicines Limited

(Vinay Rana)  
Company Secretary



Encl: As above



# NORRIS

## MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)  
 Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)  
 Telephone : (02646) 223462, 227530  
 Fax : (02646) 250126  
 E-mail : contact@norrispharma.com  
 Website : www.norrispharma.com  
 CIN : L24230GJ1990PLC086581


### STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2021

Sr. No.	Particulars	(Rs. In Lakhs)					
		Quarter Ended			Nine Months Ended		Year Ended
		31.12.2021 Unaudited	30.09.2021 Unaudited	31.12.2020 Unaudited	31.12.2021 Unaudited	31.12.2020 Unaudited	31.03.2021 Audited
i	Revenue from Operations	150.74	219.91	466.98	859.98	967.70	1225.12
ii	Other Income	1.38	0.00	0.07	3.03	2.57	5.25
iii	<b>Total Revenue (i+ii)</b>	<b>152.11</b>	<b>219.91</b>	<b>467.05</b>	<b>863.01</b>	<b>970.27</b>	<b>1230.37</b>
iv	<b>Expenses</b>						
	(a) Cost of Materials Consumed	67.28	129.86	271.21	307.00	556.93	952.68
	(b) Changes in Inventories of Finished Goods, work in Progress and stock in trade	8.02	-6.47	40.39	211.48	108.98	-78.60
	(c) Employee Benefit Expenses	50.84	68.71	98.09	180.60	227.09	310.04
	(d) Finance Costs	47.62	49.85	19.93	139.94	58.78	163.45
	(e) Depreciation and Amortisation Expense	-32.31	16.15	18.00	0.00	54.00	66.70
	(f) Other expenditure	29.39	40.66	43.64	127.04	143.24	215.44
	<b>Total Expenses (iv)</b>	<b>170.84</b>	<b>298.77</b>	<b>491.26</b>	<b>966.07</b>	<b>1149.02</b>	<b>1629.71</b>
v	<b>Profit/ (Loss) before exceptional and extraordinary items and tax (iii-iv)</b>	<b>-18.73</b>	<b>-78.86</b>	<b>-24.21</b>	<b>-103.06</b>	<b>-178.75</b>	<b>-399.34</b>
vi	Exceptional items	0	0	0	0	0	0
vii	<b>Profit/ (Loss) before extraordinary items and tax (v-vi)</b>	<b>-18.73</b>	<b>-78.86</b>	<b>-24.21</b>	<b>-103.06</b>	<b>-178.75</b>	<b>-399.34</b>
viii	Extraordinary items	0	0	0	0	0	0
ix	<b>Profit/ (Loss) before Tax (vii-viii)</b>	<b>-18.73</b>	<b>-78.86</b>	<b>-24.21</b>	<b>-103.06</b>	<b>-178.75</b>	<b>-399.34</b>
x	<b>Tax Expense</b>						
	(a) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	96.86
xi	<b>Profit / Loss after Tax</b>	<b>-18.73</b>	<b>-78.86</b>	<b>-24.21</b>	<b>-103.06</b>	<b>-178.75</b>	<b>-496.20</b>
xii	Other Comprehensive Income	0	0	0	0	0	0
	<b>Total Comprehensive Income for the period</b>	<b>-18.73</b>	<b>-78.86</b>	<b>-24.21</b>	<b>-103.06</b>	<b>-178.75</b>	<b>-496.20</b>
xiii	<b>Paid-up equity share capital ( Face Value of Rs. 10/- each)</b>	<b>992.58</b>	<b>992.58</b>	<b>992.58</b>	<b>992.58</b>	<b>992.58</b>	<b>992.58</b>
xiv	<b>- Basic and diluted</b>	<b>-0.19</b>	<b>-0.79</b>	<b>-0.24</b>	<b>-1.03</b>	<b>-1.79</b>	<b>-4.96</b>

#### Notes:

- 1) The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 12.02.2022. Limited review of the above results has been carried out by the Statutory Auditors of the company.
- 2) The Financial results of the Company have been prepared with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 and SEBI circular dated 05.07.2016.
- 3) The Company is having one segment only and therefore Segmental Reporting is not applicable.
- 4) There are no exceptional/extraordinary items during the quarter ended 31.12.2021.
- 5) Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures.

For Norris Medicines Limited

  
 Vimal D Shah  
 Managing Director

Date: 12.02.2022  
 Place: Chennai







**H.N. JADAV & CO.**  
**CHARTERED ACCOUNTANTS**

**CA Harishchandra N. Jadav**  
B. Com, FCA, DISA (ICAI)  
Mobile : 98241 25540  
harishnjadav@yahoo.com  
harishnjadav@gmail.com

C-24, GROUND FLOOR, SARDAR PATEL MUNICIPAL MARKET, SHAKTINATH, BHARUCH- 392 001.

**Limited Review Report**

**To**  
**The Board of Directors**  
**Norris Medicines Limited**  
**Ankleshwar**

We have reviewed the accompanying statement of Standalone unaudited financial results ('the statement') of **NORRIS MEDICINES LIMITED** ("the company") for the quarter ended on **31<sup>th</sup> December, 2021** and for the year to date period from 1<sup>st</sup> April, 2021 to 31<sup>th</sup> December, 2021 being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/CFD/CMD1/44/2019 date March 29, 2019. This Statement is the responsibility of the Company's Management and has been approved by the Board of directors, has been prepared in accordance with the recognition and measurement principle laid down in Indian Accounting Standards 34, "Interim Financial Reporting" (Ind AS 34) prescribed under section 133 of Companies Act 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited



